S. Senda, H. Izumi and H. Fujimura, “On uracil derivatives and related compounds. 6, 5-alkyl-2,4,6-trioxoper- hydrophyrimidine derivatives as antiphlogistics,” Arzneimittel-forschung, Vol. 17, No. 12, 1967, pp. 1519- 1523.
 K. Kitani, S. Tsuruoka, R. Miura and Y. Morita, “The effect of bucolome on the canalicular bile formation and sulfobromophthalein transport maximum in the dog,” Biochem Pharmacol, Vol. 25, No. 12, 1976, pp. 1377- 1381.
 T. Yashiki, T. Matsuzawa, T. Kondo, Y. Uda and T. Shima, “Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhy- dropyrimidine (BCP) in man. I. Identification of the metabolites of BCP in human urine,” Chem Pharm Bull, Vol. 19, No. 3, 1971, pp. 468-477.
 M. Kobayashi, M. Takagi, K. Fukumoto, R. Kato, K.Tanaka and K. Ueno, “The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan,” Drug Metab Pharmacokinet, Vol. 23, No. 2, 2008, pp. 115-119.
 H. Takahashi, T. Kashima, S. Kimura, N. Murata, T. Takaba, K. Iwade, T. Abe, H. Tainaka, T. Yasumori and H. Echizen, “Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S) warfarin clearance,” Drug Metab Dispos, Vol. 27, No. 10, 1999, pp. 1179-1186.
 T. Yashiki, T. Kondo, Y. Uda and H. Mima, “Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. II. Determination of BCP and its metabolite, 1-cyclohexyl-5-(3-hydroxybutyl)-2,4,6-trioxoperhydropyrimidine by ultraviolet absorption method,” Chem Pharm Bull, Vol. 19, No. 3, 1971, pp. 478-486.
 T. Yashiki, Y. Uda, T. Kondo and H. Mima, “Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydropyrimidine (BCP) in man. III. Gas-liquid chromatographic determination of BCP and its metabolites,” Chem Pharm Bull, Vol. 19, No. 3, 1971, pp. 487-492.
 T. Yashiki, T. Matsuzawa, M. Yamada, T. Kondo and Y. Uda, “Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydro- pyrimidine (BCP) in man. IV. Pharmacokinetics of BCP in man following oral administration,” Chem Pharm Bull, Vol. 19, No. 5, 1971, pp. 869-880.
 T. Yashiki, T. Matsuzawa, M. Yamada, T. Kondo, H. Mima, M. Yamamoto, T. Yamada, M. Nakajima and K. Doi, “Studies on the metabolic fate and the pharmacokinetics of 5-n-butyl-1-cyclohexyl-2,4,6-trioxoperhydro- pyrimidine (BCP) in man. V. Pharmacokinetics of BCP in man and in rabbit following intravenous administration of BCPNa,” Chem Pharm Bul, Vol. 19, No. 5, 1971, pp. 881-891.
 S. Kaivosaari, P. Toivonen, LM. Hesse, M. Koskinen, MH. Court and M. Finel, “Nicotine glucuronidation and the human UDPglucuronosyltransferase UGT2B10,” Mol. Pharmacol., Vol. 72, No. 3, 2007, pp. 761-768.
 S. Kaivosaari, P. Toivonen, O. Aitio, J. Sipil?, M. Koskinen, JS. Salonen and M. Finel, “Regio- and stereospecific N-glucuronidation of medetomidine: the di%erences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes,” Drug Metab. Dispos. Vol. 36, No. 3, 2008, pp. 1529-1537.
 SG. Paibir and WH. Soine, “High-performance liquid chromatographic analysis of phenobarbital and phenobarbital metabolites in human urine,” J Chromatogr B Biomed Sci, Vol. 691, No. 1, 1997, pp. 111-117.
 L. Luukkanen, J. Taskinen, M. Kurkela, R. Kostiainen, J. Hirvonen and M. Finel, “Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyl- transferases,” Drug Metab Dispos, Vol. 33, No. 7, 2005, pp. 1017-1026.
 S. Ohno and S. Nakajin, “Determination of mRNA Expression of HumanUDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction,” Drug Metab Dispos, Vol. 37, No. 1, 2009, pp. 32-40.
 PI. Mackenzie, KW. Bock, B. Burchell, C. Guillemette, S. Ikushiro, T. Iyanagi, JO. Miners, IS. Owens, DW. Nebert “Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily.” Pharmacogenet. Genomics, Vol. 15, 2005, pp. 677-685.
 CD. King, MD. Green, GR. Rios, BL. Coffman, IS. Owens, WP. Bishop and TR. Tephly, “The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1,” Arch. Biochem. Biophys., Vol. 332, No. 1, 1996, pp. 92-100.
 H. Kanoh, M. Tada, S. Ikushiro and K. Mohri, “Characterization of Bucolome N-Glucuronide Formation: Tissue specificity and Identification of Rat UDP-Glucuronosyl- transferase Isoform (s),” Pharmacology and Pharmacy, 2011, in press.